Join the Head and Neck Cancer group to help and get support from people like you.
Head and Neck Cancer News (Page 2)
Related terms: Oral Cancer
Cancers Among the Young Are Rising Worldwide
WEDNESDAY, Sept. 6, 2023 – Cancer is surging among people under 50, a new global study reveals. Over the past 30 years, new cases have increased 79% worldwide in that age bracket, according to a...
Zolbetuximab Plus CAPOX Beneficial for Advanced mG/GEJ Adenocarcinoma
FRIDAY, Sept. 1, 2023 – For patients with human epidermal growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ)...
K-ECAN Tool Can Predict Esophageal, Gastric Cardia Adenocarcinoma
MONDAY, Aug. 28, 2023 – The Kettles Esophageal and Cardia Adenocarcinoma predictioN (K-ECAN) Tool can predict incident esophageal adenocarcinoma (EAC) and gastric cardia adenocarcinoma (GCA) using...
AI Pipeline Can Accurately Measure Sarcopenia in Head and Neck Cancer
MONDAY, Aug. 14, 2023 – A fully automated deep learning pipeline can accurately measure sarcopenia in head and neck squamous cell carcinoma (HNSCC), which is associated with disease outcomes,...
FDA Approves Merck’s Gardasil 9 for the Prevention of Certain HPV-Related Head and Neck Cancers
KENILWORTH, N.J.--(BUSINESS WIRE) June 12, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Keytruda (pembrolizumab) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) June 11, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Bristol-Myers Squibb’s Opdivo (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing
PRINCETON, N.J.--(BUSINESS WIRE) March 6, 2018 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License...
Bristol-Myers Squibb’s Opdivo (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
PRINCETON, N.J.--(BUSINESS WIRE) November 10, 2016 --Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab)...
FDA Approves Merck’s Keytruda (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
KENILWORTH, N.J.--(BUSINESS WIRE)--August 5, 2016 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Teikoku Pharma USA, Inc. Announces FDA Approval of Docetaxel Injection, Non-Alcohol Formula
San Jose, Calif. - December 28, 2015 - Teikoku Pharma USA (TPU) announced today that the U.S. Food and Drug Administration ("FDA") has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel...
FDA Approves Erbitux to Treat Late-stage Head and Neck Cancer
SILVER SPRING, Md., Nov. 7, 2011 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage...
Ask a question
To post your own question to this support group, sign in or create an account.